HOME >> MEDICINE >> NEWS
Misdosing common for powerful anti-clotting drugs

Because of inaccuracies in prescribing, 42 percent of patients rushed to emergency rooms with symptoms of a heart attack received doses of powerful drugs intended stop clotting in coronary arteries outside of the recommended range, a new analysis by Duke Clinical Research Institute (DCRI) cardiologists has found.

While numerous clinical trials have proven that these drugs can save lives, correct dosing is crucial, the researchers said, since the therapeutic window is narrow. Too much of the drug can lead to bleeding episodes, while too little may be ineffective at stopping the clotting process.

The Duke researchers believe that when evaluating these patients in emergency rooms, physicians should spend a little more time clarifying information such as weight and kidney function which are necessary for accurate dosing. The researchers also hope that the results of their analysis provide concrete steps to improve safety thereby increasing physician confidence in using these drugs on high risk patients, who have the most to gain.

"These drugs are clearly beneficial, and when dosed correctly, are also safe," said Duke cardiologist Karen Alexander, M.D., lead investigator of the study published Dec. 28, 2005, in the Journal of the American Medical Association.

The drugs in question unfractionated heparin (UFH), low-molecular-weight heparin (LMWH) and glycoprotein IIb/IIIa inhibitors work by either preventing the aggregation of platelets in coronary arteries or interfering with the formation of blood clots. The drugs are typically given within the first 24 hours of heart attack symptoms, and it is not uncommon for patients to receive combinations of these drugs during their hospital stay. Doses are determined by patient-specific data incorporated into standard prescribing algorithms.

"Our analysis, which includes patients treated in all types of hospitals across the country shows that dosing errors occur more often in vulnerabl
'"/>

Contact: Richard Merritt
Merri006@mc.duke.edu
919-684-4148
Duke University Medical Center
27-Dec-2005


Page: 1 2 3

Related medicine news :

1. Refusal of medical and surgical interventions common among chronically ill elderly
2. Needle-stick injuries are common but unreported by surgeons in training
3. Sleep-related breathing disorder common among aggressive, bullying schoolchildren
4. Nearly half of children in Kenya with common type of severe malaria affected neurologically
5. Scientists identify cells responsible for relapse after treatment in common childhood cancer
6. Infection detectives use disease fingerprints to track common infections in children
7. Anxiety disorders surprisingly common yet often untreated
8. Mental illnesses appear common among veterans returning from Iraq and Afghanistan
9. Sleep apnea common, but undiagnosed, among pacemaker patients
10. Use of common pain relievers associated with increased risk of blood pressure in men
11. Updated rates of common US neurological disorders

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Misdosing common for powerful anti clotting drugs

(Date:7/24/2014)... (PRWEB) July 24, 2014 The ... Association (AOA) and the Entertainment Industries Council (EIC) ... TV series American Horror Story on a first-of-its-kind ... the dramatic realities of illegal and unsafe lens ... which has already reached tens-of-thousands, is now releasing ...
(Date:7/24/2014)... -- A new formulation of a powerful narcotic painkiller ... drug has been approved by the U.S. Food and ... Purdue Pharma, the pill is a combination of the ... euphoric effects of oxycodone. The naloxone is only activated ... according to the FDA. While Targiniq has only ...
(Date:7/24/2014)... 17, 2014, Cleveland: Could the body,s own immune system ... associated with conditions like chronic epilepsy, Alzheimer,s dementia and ... study published online by PLOS ONE . , ... known as S100B, which serves as a biomarker for ... brain and spinal column. However, following a brain injury, ...
(Date:7/24/2014)... July 24, 2014 National Analysts Worldwide, ... that it will operate globally under the name, ... a woman-owned Employee Stock Ownership Plan (ESOP) organization led ... McDonald, Ph.D . The firm guides market strategy ... analytics. , Said McDonald, “We wanted our name ...
(Date:7/24/2014)... The report, “Feed Palatability Enhancers & Modifiers ... Poultry, Cattle, Pets, Aquaculture, and Others) - Global Trends ... palatability enhancers & modifiers market with an analysis and ... of types of feed flavors, sweeteners, and text rants. ... spread through 275 pages and in-depth TOC on "Feed ...
Breaking Medicine News(10 mins):Health News:Optometric Professionals Team with Hollywood for Second Installment of Video Campaign 2Health News:Optometric Professionals Team with Hollywood for Second Installment of Video Campaign 3Health News:Optometric Professionals Team with Hollywood for Second Installment of Video Campaign 4Health News:FDA Approves Hard-to-Abuse Narcotic Painkiller 2Health News:Immune response may cause harm in brain injuries, disorders 2Health News:National Analysts Worldwide Announces a Change of Name to NAXION 2Health News:National Analysts Worldwide Announces a Change of Name to NAXION 3Health News:Feed Palatability Enhancers & Modifiers Market Worth $3172.6 Million by 2019 - Report by MarketsandMarkets 2Health News:Feed Palatability Enhancers & Modifiers Market Worth $3172.6 Million by 2019 - Report by MarketsandMarkets 3Health News:Feed Palatability Enhancers & Modifiers Market Worth $3172.6 Million by 2019 - Report by MarketsandMarkets 4
(Date:7/24/2014)...  Blueprint Medicines (Blueprint), a leader in discovering highly ... announced the appointment of Jeffrey Albers as ... Algeta ASA, where he served on the executive management ... Bayer. Mr. Albers succeeds Alexis Borisy , co-founder ... Rock Ventures, who will remain an active member of ...
(Date:7/24/2014)... SAN DIEGO , July 24, 2014 /PRNewswire/ ... the industry leader in bioactive lipid-targeted therapeutics, reported ... trial where ASONEP™ is being investigated as a ... patients that have failed at least one therapy ... and no more than one mTOR inhibitor (e.g., ...
(Date:7/24/2014)... 24, 2014  Market Diagnostics International LLC ("MDxI") ... LabFile , a data resource that sets a ... universe and identifying target In Vitro Diagnostics (IVD) ... that provides IVD manufacturers with accurate and comprehensive ... clear and consistent definitions of laboratory categories and ...
Breaking Medicine Technology:Blueprint Medicines Appoints Jeffrey Albers as Chief Executive Officer 2Lpath Reports Interim Data From Phase 2a Study for Anti-Cancer Drug, ASONEP 2Lpath Reports Interim Data From Phase 2a Study for Anti-Cancer Drug, ASONEP 3Lpath Reports Interim Data From Phase 2a Study for Anti-Cancer Drug, ASONEP 4MDxI Launches Data Resource Setting New Standard for Defining and Targeting US Clinical Laboratory Universe 2
Cached News: